Cadrenal Therapeutics Inc (CVKD)

$11.24 -0.20 (-1.75%)
Market Cap 22.50M
Revenue (ttm) 0.00
Net Income (ttm) -10.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 46,000
Avg Vol 22,220
Day's Range N/A - N/A
Shares Out 1.97M
Stochastic %K 21%
Beta 1.10
Analysts Strong Sell
Price Target $35.67

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-...

Industry: Biotechnology
Sector: Healthcare
Phone: 904 300 0701
Address:
822 A1A North, Suite 306, Ponte Vedra, United States
PenkeTrading
PenkeTrading Jun. 24 at 5:58 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Cadrenal Therapeutics, Inc. Common Stock. Is that bullish or bearish? $CVKD #Cadrenal #RsiOversold #NASDAQ
0 · Reply
Jhon05
Jhon05 Jun. 23 at 3:26 PM
$CVKD Only 1.9 M float so nice.
0 · Reply
Jhon05
Jhon05 Jun. 23 at 3:24 PM
$CVKD ADDED
1 · Reply
Greeny1968
Greeny1968 Jun. 23 at 2:13 PM
$CVKD Now is the last call for sure!
2 · Reply
Greeny1968
Greeny1968 Jun. 20 at 7:29 PM
$CVKD Where’s @Dazkusmoney? 🤣
1 · Reply
Jhon05
Jhon05 Jun. 20 at 3:07 PM
$CVKD Last Call
1 · Reply
PaidBashar
PaidBashar Jun. 17 at 11:34 PM
$CVKD seriously why would you do this to yourself?
0 · Reply
Jhon05
Jhon05 Jun. 17 at 5:48 PM
$CVKD Looks Good 👍 . SOON
1 · Reply
Dazkusmoney
Dazkusmoney Jun. 14 at 11:51 AM
$CVKD Obviously missing being loved as a child. 😂 Most likely life in general….sad.
1 · Reply
StayPresent
StayPresent Jun. 14 at 1:10 AM
$CVKD Dazkus, you still jerking off to the potential on this one? F’in clown.
0 · Reply
Latest News on CVKD
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Jun 12, 2025, 8:00 AM EDT - 12 days ago

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Jun 4, 2025, 8:00 AM EDT - 20 days ago

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 15, 2025, 7:30 AM EDT - 5 weeks ago

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 6 weeks ago

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Apr 17, 2025, 9:40 AM EDT - 2 months ago

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Apr 3, 2025, 8:00 AM EDT - 2 months ago

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Mar 13, 2025, 4:05 PM EDT - 3 months ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Mar 4, 2025, 8:00 AM EST - 4 months ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

ABT

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 6, 2025, 9:00 AM EST - 4 months ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Feb 5, 2025, 9:00 AM EST - 4 months ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 8:44 AM EST - 5 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 31, 2024, 8:00 AM EST - 6 months ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Dec 18, 2024, 9:00 AM EST - 6 months ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 19, 2024, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Nov 12, 2024, 9:00 AM EST - 8 months ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 7, 2024, 9:00 AM EST - 8 months ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Nov 1, 2024, 8:00 PM EDT - 8 months ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Oct 24, 2024, 9:00 AM EDT - 8 months ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Oct 23, 2024, 9:00 AM EDT - 8 months ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Sep 23, 2024, 4:15 PM EDT - 9 months ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Aug 22, 2024, 9:00 AM EDT - 10 months ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Aug 20, 2024, 9:00 AM EDT - 11 months ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 11 months ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA ELUT EUDA GDTC GOSS GOVX IMRN

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Aug 14, 2024, 9:00 AM EDT - 11 months ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Aug 7, 2024, 4:05 PM EDT - 11 months ago

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

Aug 6, 2024, 9:00 AM EDT - 11 months ago

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

ABT

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Jun 11, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

ABT

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 23, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

May 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Apr 11, 2024, 4:30 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Apr 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Mar 11, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Feb 26, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Feb 8, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Jan 31, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 24, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Jan 4, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Dec 19, 2023, 9:00 AM EST - 1 year ago

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization

Dec 12, 2023, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

Nov 30, 2023, 4:15 PM EST - 1 year ago

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Nov 9, 2023, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 9, 2023, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 28, 2023, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

Aug 10, 2023, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases

Aug 1, 2023, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

Jul 24, 2023, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

PenkeTrading
PenkeTrading Jun. 24 at 5:58 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Cadrenal Therapeutics, Inc. Common Stock. Is that bullish or bearish? $CVKD #Cadrenal #RsiOversold #NASDAQ
0 · Reply
Jhon05
Jhon05 Jun. 23 at 3:26 PM
$CVKD Only 1.9 M float so nice.
0 · Reply
Jhon05
Jhon05 Jun. 23 at 3:24 PM
$CVKD ADDED
1 · Reply
Greeny1968
Greeny1968 Jun. 23 at 2:13 PM
$CVKD Now is the last call for sure!
2 · Reply
Greeny1968
Greeny1968 Jun. 20 at 7:29 PM
$CVKD Where’s @Dazkusmoney? 🤣
1 · Reply
Jhon05
Jhon05 Jun. 20 at 3:07 PM
$CVKD Last Call
1 · Reply
PaidBashar
PaidBashar Jun. 17 at 11:34 PM
$CVKD seriously why would you do this to yourself?
0 · Reply
Jhon05
Jhon05 Jun. 17 at 5:48 PM
$CVKD Looks Good 👍 . SOON
1 · Reply
Dazkusmoney
Dazkusmoney Jun. 14 at 11:51 AM
$CVKD Obviously missing being loved as a child. 😂 Most likely life in general….sad.
1 · Reply
StayPresent
StayPresent Jun. 14 at 1:10 AM
$CVKD Dazkus, you still jerking off to the potential on this one? F’in clown.
0 · Reply
Jhon05
Jhon05 Jun. 12 at 1:55 PM
$CVKD 🚨🚨🚨🚨🚨
0 · Reply
topstockalerts
topstockalerts Jun. 12 at 1:52 PM
$CVKD this setup continues to provide opportunities.. stay tuned!🚨🚨
0 · Reply
Jhon05
Jhon05 Jun. 12 at 1:44 PM
$CVKD BREAKOUT 👀👀
0 · Reply
Jhon05
Jhon05 Jun. 12 at 1:00 PM
$CVKD https://finance.yahoo.com/news/cadrenal-therapeutics-highlights-research-anticoagulation-120000058.html?guccounter=1
0 · Reply
PaidBashar
PaidBashar Jun. 11 at 8:06 PM
$CVKD Boustead
0 · Reply
PaidBashar
PaidBashar Jun. 10 at 3:31 PM
$CVKD this company has less Property, Plant, and Equipment on its balance sheet than I have in my living room
1 · Reply
Dazkusmoney
Dazkusmoney Jun. 8 at 12:50 AM
$CVKD Sorry but I couldn’t help help myself from posting this! Greatest stock prediction tools ever! 😂 https://youtu.be/p0vXXlQQoI0?si=LwpVLO9RByuwQiu6
1 · Reply
Jhon05
Jhon05 Jun. 6 at 7:33 PM
$CVKD
0 · Reply
Jhon05
Jhon05 Jun. 5 at 2:14 PM
$CVKD it's will breakout
0 · Reply
RiskRewardLab
RiskRewardLab Jun. 5 at 10:05 AM
$CVKD Was on my watchlist. Known runner ! GLMD low floater bio about to release major news. 5-7$ is not that far away on volume. No dilution and 20M$ cash
0 · Reply
jParkz
jParkz Jun. 4 at 8:00 PM
News out Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 https://marketwirenews.com/news-releases/cadrenal-therapeutics-to-engage-potential-partners-a-6414956521794834.html $CVKD
0 · Reply
Jhon05
Jhon05 Jun. 4 at 4:31 PM
$CVKD Looks like runner until jun. 19
0 · Reply